Jacobs Levy Equity Management’s Anterix ATEX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-8,500
Closed -$337K – 957
2024
Q2
$337K Buy
+8,500
New +$275K ﹤0.01% 882
2022
Q2
– Sell
-5,700
Closed -$330K – 999
2022
Q1
$330K Buy
+5,700
New +$312K ﹤0.01% 907

Other funds holding ATEX

Jacobs Levy Equity Management's ATEX Position: Q3 2024 in Review

Jacobs Levy Equity Management sold out of Anterix (ATEX) in Q3 2024, closing a stake of 8,500 shares — an estimated $337K sold.

Jacobs Levy Equity Management first reported a position in ATEX in Q1 2022 and held it in 2 quarters. The position peaked at $337K in Q2 2024. 129 funds tracked by Wall St. Rank hold ATEX as of Q3 2024.

  • Jacobs Levy Equity Management reported no remaining Anterix position as of Q3 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 8,500 Anterix shares in Q3 2024, an estimated $337K.
  • Jacobs Levy Equity Management first reported a position in Anterix in Q1 2022 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Anterix position peaked at $337K in Q2 2024.
  • 129 funds tracked by Wall St. Rank held Anterix as of Q3 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2024, filed 14 Nov 2024.